Viewpoint Molecular Targeting Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 27

Employees
  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $14.3M

  • Investors
  • 7

Viewpoint Molecular Targeting General Information

Description

Developer of pharmaceutical drugs and therapies intended for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma. The company's product targets a cell surface receptor that is found on the cell surface of metastatic melanoma cells and can be used to determine the location and extent of cancerous tumors in the body, enabling health professionals to direct a lethal dose of radiation precisely to cancer cells in the body.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 2500 Crosspark Road
  • Coralville, IA 52241
  • United States
+1 (319) 000-0000

Viewpoint Molecular Targeting Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Viewpoint Molecular Targeting Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 14-Jan-2021 $14.3M 000.00 Completed Generating Revenue
3. Grant 20-Sep-2019 00.00 Completed Generating Revenue
2. Grant 08-Sep-2017 $2M Completed Generating Revenue
1. Grant 31-Aug-2016 $1.2M Completed Startup
To view Viewpoint Molecular Targeting’s complete valuation and funding history, request access »

Viewpoint Molecular Targeting Executive Team (5)

Name Title Board Seat Contact Info
Thijs Spoor Chief Executive Officer & Board Member
Frances Johnson MD Co-Founder, Chief Operating Officer & Board Member
Amos Hedt Chief Business Strategy Officer
Michael Schultz Ph.D Co-Founder, Board Member and Chief Science Officer
You’re viewing 4 of 5 executive team members. Get the full list »

Viewpoint Molecular Targeting Board Members (9)

Name Representing Role Since
Cameron Gray Ph.D Self Board Member 000 0000
Charles Link Jr. Self Board Member 000 0000
Curtis Nelson Self Chairman 000 0000
Frances Johnson MD Viewpoint Molecular Targeting Co-Founder, Chief Operating Officer & Board Member 000 0000
Frank Morich Ph.D Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Viewpoint Molecular Targeting Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Viewpoint Molecular Targeting Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Iowa Seed Fund Venture Capital Minority 000 0000 000000 0
Next Level Ventures Venture Capital Minority 000 0000 000000 0
Tribe Capital Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
National Cancer Institute Government 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »